Patients and Physicians Express Desire to Switch to Transdermal Drug Delivery, Finds Frost & Sullivan The growing challenge of medication adherence has significant health and financial implications

MOUNTAIN VIEW, Calif., July 11, 2013 /PRNewswire/ -- The $82 billion U.S. drug delivery market is showing no signs of saturation, with major patent expiries, generic competition, tightening Food and Drug Administration (FDA) regulations, and emerging drug delivery systems continuing to provide momentum. Among the 15 drug delivery systems surveyed by Frost & Sullivan, physicians prefer topical delivery, either as a transdermal patch or topical gel/cream, and expressed willingness to switch their current mode of therapy to one available in these forms.

A new end-user survey of more than 220 physicians and 650 patients by Frost & Sullivan, the Drug Delivery Technology: End-User Preferences, Utilization and Perceptions analysis (http://www.lifesciences.frost.com), finds that regardless of disease area, physicians select drug delivery methods that drive consistent patient compliance and effective outcomes. The survey traces usage patterns, analyzes preferences and opportunities among physicians and patients, and assesses their willingness to switch therapies based on the drug delivery method.

DRUG DELIVERY METHODS AND DISEASE TYPES COVERED

Delivery Method

Disease Type

Oral drug delivery

Type 1 diabetes

Nasal drug delivery

Type 2 diabetes

Transdermal drug delivery

Obesity

Topical drug delivery

Deep vein thrombosis

Subcutaneous injection (autoinjector)

Arterial thrombosis

Subcutaneous injection (prefilled syringe)

Atrial fibrillation/arrhythmia

Intramuscular injection (autoinjector)

Ischemic heart disease

Intramuscular injection (prefilled syringe)

Migraines

Intradermal injection

Multiple Sclerosis

Intravenous injection

ADHD

Intravenous infusion

Schizophrenia

Implantable infusion pump

Alzheimer's disease

External infusion pump

Depression

Implant

Ulcerative colitis

Rectal drug delivery

Crohn's disease


Psoriasis


Rheumatoid arthritis

For more information on this research, please email Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

The route of administration and drug delivery technology has a huge bearing on the adoption of, and compliance with, new as well as existing drugs. Among the surveyed physicians, only a quarter were considered early adopters of new drug delivery forms. Accordingly, manufacturers must listen to actual selection criteria and level of satisfaction data collected from end-users to find commercial success among medical practitioners.

"All things considered, physicians usually lean toward the treatment they feel will be most acceptable to their patients in order to ensure good compliance," said Frost & Sullivan Vice President of Global Research Monali Patel Shastry.

These indicators are highly relevant in the current market scenario, wherein medication adherence is a growing concern, with momentous medical and economic consequences.

"When selecting the optimal drug delivery method, reimbursement incentives for improving adherence and impact on formulary decisions are proven to be important factors," noted Frost & Sullivan Life Sciences Senior Industry Analyst Deborah Toscano. "Drug development pipelines are full of innovative drugs and biologics, and differentiation is increasingly important in this crowded market to gain and maintain market share."

It is important to note the drivers of satisfaction and selection are not always the same across diseases and methods. For example, the several novel oral therapies for multiple sclerosis recently introduced offer significant advantages over the standard of care injectable therapies. However, more than 55 percent of physicians treating multiple sclerosis are likely to switch from the currently prescribed branded drug if the drug were available in a transdermal patch form, while 54 percent of the physicians treating migraines would prefer to switch to a drug using nasal administration.

This is in line with the 58 percent of multiple sclerosis patients willing to use a transdermal patch, and 50 percent of migraine patients willing to use a nasally administered drug. Further, 57 percent of physicians treating type 2 diabetes are most willing to switch from oral or injectable drugs to a topical treatment.

The Drug Delivery Technology: End-User Preferences, Utilization and Perceptions analysis is generated by Frost & Sullivan's global Life Sciences practice.  Related research includes: Analysis of the Global Type 2 Diabetes Therapeutics Market, United States Market for Rheumatoid Arthritis Pharmacotherapeutics, and Strategic Analysis of Anti-Obesity Prescription Drug Development. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

Connect with Frost & Sullivan on social media, including Twitter, Facebook, SlideShare and LinkedIn, for the latest news and updates.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:         Gain access to visionary innovation

Drug Delivery Technology: End-User Preferences, Utilization and Perceptions

Contact:
Britni Myers
Corporate Communications – North America
P: 210.477.8481
F: 210.348.1003
E: britni.myers@frost.com 
Twitter: @Frost_Sullivan
Facebook: Frost & Sullivan

http://www.frost.com

SOURCE Frost & Sullivan



RELATED LINKS
http://www.frost.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.